secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001493152-24-020128
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics preparing Phase II trial for concussion drug ONP-002; secures CRO, optimizes formulation
--------------------------------------------------------------------------------

- ONP-002 intranasal neurosteroid for mild TBI (concussion) advances to Phase II after positive Phase I safety.
- Partnering with Avance Clinical for Phase IIa at level one trauma centers in Australia.
- Formulation optimized to increase active compound percentage and target brain absorption within minutes.
- Estimated 69 million concussion cases globally annually; up to 20% develop post-concussion syndrome.
- Adequate intranasal device supply secured for upcoming trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224020128/0001493152-24-020128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224020128/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer